Author(s)
Purpose
- Pathology:
Male genital diseases
Psychiatry/psychology
- Disease:
Erectile dysfunction
- Objective:
To describe Erectile Dysfunction specific health-related quality of life and treatment satisfaction
- Population for intended use:
Adult
Male
Characteristics
- Type of instrument:
Health-Related Quality of Life - HRQL (incl. health status)
Patient satisfaction
- Administration mode:
Self-administered
- Number of items:
Pre-treatment version: 10; Post-treatment version: 16
- Recall/Observation period:
8 weeks or 4 weeks
Language(s)
- Original language:
English for the USA
- List of existing translations:
The translations listed below may not have undergone a full linguistic validation process and may require further work to be suitable for use in a study.
This list of translations is subject to constant changes, therefore please check the status of translations with MAPI Research Trust / the developers / copyright holders / distributors.
SLQQ
| Chinese for Hong Kong* |
| Chinese for Taiwan* |
| Spanish for Spain |
* Performed by the MAPI Institute
Bibliographic reference(s) of the original questionnaire
Neil Baum, Eduardo Randrup, Dan Junot, Steven Hass. Prostaglandin E1 vs. Sex Therapy in the Management of Psychogenic Erectile Dysfunction. International Journal of Impotence Research 2000 12, 191-4
RJ Wilke, SL Hass, G Borg. Intracavernosal Alprostadil Therapy for Diabetics : Quality of Life Results from a Cliical Trial in Europe and South Africa. in E Meulemann, G Nijeholt, D Vanderschueren, ed. The 8th World Meeting on Impotence Research (Bologna, Italy; Monduzzi Editore, August 1998)
Last update: March 2012
Last update in collaboration with the author: December 2002
